Novartis·Healthcare / Pharmaceuticals·Prague, Czech Republic·Founded 1996·Last verified 31 May 2026
50
out of 100
Making progressPending ReviewMixed evidence· 12 src

Novartis demonstrates solid operational decarbonization and supply-chain engagement but relies heavily on carbon credits for claimed neutrality. Nature strategy is nascent. A 2022 NGO assessment flagged 'very low integrity' targets—since partially addressed by SBTi validation—and the company retains trade association memberships with poor climate records.

The calculation

Every score shows its working.

Same formula for every company. No curve. No private weighting.

SINK = (0.3 × Base + 0.7 × Performance) × Scale
Industry base impact
Healthcare / Pharmaceuticals sector ceiling.
45 / 100
Performance score
Sum of the 10 rubric questions, scored 0–10 each.
67 / 100
Raw score
Weighted average before scale penalty.
(0.3 × 45) + (0.7 × 67) = 60.4
Scale penalty
Multiplier based on absolute emissions volume — physics-first.
× 0.82
Final score
Rounded. Making progress.
50 / 100
The ten questions

Where Novartis is strong, and where it isn't.

Strongest on Carbon Footprint — Operations and Energy Source (8/10, 8/10). Weakest on Controversies & Red Flags and Nature & Biodiversity Impact (3/10, 5/10).

Where the evidence comes from

Every document used, listed.

12 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.

[1]Third-party verified
Ditch Carbon — Novartis Profile
Ongoing
Q1Q2Q3
View →
[2]Self-reported
Novartis Reporting Criteria 2024
2024
Q1
View →
[3]Public record
Drug and Device World — Novartis Net-Zero March
2025
Q1Q3
View →
[4]Self-reported
Novartis Impact & Sustainability Report 2024
2024
Q2
View →
[5]Self-reported
Novartis Climate & Environmental Sustainability
Ongoing
Q2Q4Q8
View →
[6]Self-reported
Novartis Renewable Electricity Announcement
2024
Q4
View →
[7]Public record
GreenTech Lead — Novartis 2025 Sustainability Update
2025
Q4Q6Q7
View →
[8]Self-reported
Novartis Q4 2024 Impact & Sustainability Update
2024
Q5
View →
[9]Third-party verified
WBCSD Roadmap to Nature Positive — Pharmaceutical
Unknown
Q5
View →
[10]Self-reported
Novartis Water Impact & Management
Ongoing
Q7
View →
[11]Self-reported
Novartis Targets & Commitments Hub
Ongoing
Q6Q7
View →
[12]Third-party verified
InfluenceMap — Novartis Climate Policy Engagement
Unknown
Q10
View →

If you believe a source has been misread or a newer version exists, submit a challenge.

Novartis in context

Where Novartis sits among healthcare / pharmaceuticals peers.

Among the 11 major healthcare / pharmaceuticals brands we've scored, Novartis is tied =2nd of 11, with 2 others.

=2/11
Novartis's rank
46
Industry average
39
Industry low
52
Industry high
How this score has moved

Novartis's score over time.

today

Score history begins 4 April 2026.

As Novartis's score updates, the trajectory will appear here.

We're backfilling historical scores for FTSE 100 and S&P 100 companies over the coming weeks.

What's being contested

This score is not currently being contested.

Every challenge is published. We'd rather be corrected than wrong — that's the whole point.

No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel, specializing in oncology, cardiology, immunology, and infectious diseases. One of the sector's largest by revenue, it operates manufacturing sites globally and maintains extensive supply chains across chemical procurement and active pharmaceutical ingredients.

Founded
1996
Headquarters
Prague, Czech Republic
Employees
~78,000
Annual revenue
~$51.7B
Company website ↗
Track Novartis

We'll let you know when the score moves.

Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.

THE SUNDAY RUNDOWN

Which companies moved this week, and why.

One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.

No spam. Unsubscribe in one click.

HOW SINK STAYS INDEPENDENT

Readers and institutions support our work. Companies can pay to submit evidence we couldn't find. Neither type of payment changes a score.